Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Capital Expenditures (2024 - 2025)

Indivior Pharmaceuticals (INDV) has 2 years of Capital Expenditures data on record, last reported at $20.0 million in Q3 2025.

  • For Q3 2025, Capital Expenditures rose 185.71% year-over-year to $20.0 million; the TTM value through Sep 2025 reached $49.0 million, changed N/A, while the annual FY2023 figure was $8.0 million, N/A changed from the prior year.
  • Capital Expenditures reached $20.0 million in Q3 2025 per INDV's latest filing, up from $17.0 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $20.0 million in Q3 2025 and bottomed at $2.0 million in Q1 2024.